Selva Therapeutics is focused on developing innovative therapeutics for infectious diseases, with its lead candidate, SLV213, being a novel small molecule antiviral therapy. SLV213 demonstrates broad-spectrum antiviral activity against various viruses, including SARS-CoV-2, Ebola, Nipah, and Marburg, as well as the parasite responsible for Chagas disease. The drug functions as a potent inhibitor of cathepsin L, a host cysteine protease that viruses utilize to enter human cells. This unique mechanism of action allows SLV213 to potentially remain effective against viral mutations and to be used in combination with other antiviral treatments, enhancing their efficacy significantly.

The clinical development of SLV213 has shown promising results, with successful completion of a Phase 1 safety trial and ongoing preparations for a Phase 1b trial. Preclinical studies have indicated that SLV213 can effectively reduce viral loads and protect against lung damage associated with COVID-19. Its oral formulation makes it suitable for outpatient treatment, particularly for mild to moderate cases. Selva Therapeutics aims to position SLV213 as a critical option in the COVID-19 treatment landscape, especially given the challenges posed by emerging variants and the limitations of existing therapies.

United States

Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego.

Selva Therapeutics

Company Details